THE ROLE OF METFORMIN IN THE TREATMENT OF PATIENTS WITH POLYCYSTIC OVARY SYNDROME
Abstract
Background Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting wo- men of reproductive age in 1020 % under the American criteria and 1522 % under the European criteria. It is presented with disorders in the menstrual cycles, hirsutism, acne, alopecia and obesity. Nowadays, metformin drug has joined the traditional and establis- hed methods of treatment that are mainly focused to prevention of the leading symptom (hirsutism or irregular periods or fertility problems). Metformin is a peroral anti-diabetic agent that increases insulin sensitivity. Insulin stimulates androgen secretion by the ovari- an stroma and appears to affect the normal development of ovarian follicles by suppres- sing apoptosis and permitting the survival of follicles otherwise destined to disappear. The long term sequelae of insulin resistance may be the development of insulin-dependent dia- betes and dyslipidemia. Conclusions The results of meta-analysis and other studies confirm that metformin prevents the pro- gress of insulin resistance, has a favourable impact on loosing weight and is effective in induction of ovulation, mainly in clomiphen resistant women.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
